Eastern Cooperative Oncology Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eastern Cooperative Oncology Group sits in the top decile of US sponsors by registered trial count (#198 of 15,742 sponsors by registered trial count).
Eastern Cooperative Oncology Group: 141 sponsored US clinical trials, 4 recruiting.
Eastern Cooperative Oncology Group sponsors 141 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 121 completed. 37 of these trials are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bladder Cancer, with 3 trials.
Top-decile sponsor footprint
Eastern Cooperative Oncology Group ranks in the top decile of sponsors by registered trial count (#198 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
121 of 131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
141 total, page 3 of 3
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome
NCT00003601
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
NCT00003614
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
NCT00003308
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
NCT00003518
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
NCT00003376
Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed
NCT00003649
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
NCT00003353
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
NCT00003283
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
NCT00003129
Combination Chemotherapy in Treating Women With Breast Cancer
NCT00003519
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
NCT00003153
Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer
NCT00003236
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
NCT00003237
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed
NCT00003235
Flecainide in Treating Patients With Chronic Neuropathic Pain
NCT00002996
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
NCT00003329
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes
NCT00003138
Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
NCT00002997
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00003008
Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy
NCT00003010
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00003150
Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer
NCT00003172
Interleukin-12 in Treating Patients With Multiple Myeloma
NCT00003149
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
NCT00002868
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
NCT00003027
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00002826
Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract
NCT00002914
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
NCT00003017
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00002878
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
NCT00002934
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
NCT00003057
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
NCT00002888
Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
NCT00002922
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
NCT00002881
Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
NCT00002668
Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer
NCT00002667
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
NCT00002646
High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed
NCT00002650
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
NCT00002632
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
NCT00002514
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
NCT00002520
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 87 |
| Phase 3 | 37 |
Therapeutic Areas
What is open in the Eastern Cooperative Oncology Group pipeline
4 recruiting of 141 indexed (3% open); 121 completed (86%).
Phase mix: 37 late (III/IV) vs 90 early (I/II) (early-phase heavy).
Top condition: Bladder Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eastern Cooperative Oncology Group: open-pipeline peers nationwide
Peers matched on 141 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Eastern Cooperative Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 141 trials (± recruiting share)
- Case Western Reserve University · 141 trials · 16% recruiting
- Purdue University · 141 trials · 10% recruiting
- Johnson & Johnson Vision Care · 142 trials · 1% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Merz North America · 3% recruiting · 35 trials
- VIVUS · 3% recruiting · 35 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
Related
What to do with this Eastern Cooperative Oncology Group page
141 registered trials is a research-attention snapshot, not an endorsement of Eastern Cooperative Oncology Group or any single study.
- 4 of Eastern Cooperative Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bladder Cancer is the condition Eastern Cooperative Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bladder Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eastern Cooperative Oncology Group pipeline card: 141 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.